Aethlon Medical, Inc. (AEMD)
Chart Events
Performance Outlook
| Previous Close | 0.5898 |
| Open | 0.5668 |
| Bid | 0.5800 x 1200 |
| Ask | 0.5989 x 1000 |
| Day's Range | 0.5668 - 0.6150 |
| 52 Week Range | 0.2300 - 2.4600 |
| Volume | |
| Avg. Volume | 1,113,159 |
| Market Cap | 13.742M |
| Beta (5Y Monthly) | 1.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AEMD
Related Research
- Aethlon Medical, Inc.Analyst Report: Hologic, Inc.Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (64% of total sales, boosted by pandemic), breast health (21% of sales, suppressed by pandemic), surgical (12%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (75%), followed by Europe (16%), Asia (6%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.RatingFair ValueEconomic Moat6 days agoMorningstar
- PR Newswire
Aethlon Medical to Present at Sequire Biotechnology Conference on February 2nd, 2023
Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, announced today that it will be presenting virtually at the upcoming Sequire Biotechnology Conference on Thursday, February 2nd, at 10:00 AM ET. Steven LaRosa, M.D., Chief Medical Officer and Chief Scientific Officer of Aethlon Medical, will be giving the presentation.
- PR Newswire
Aethlon Medical Announces Contract with NAMSA to Advance Hemopurifier Clinical Programs in Cancer
Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious diseases, today announced that it has entered into an agreement with NAMSA, a world leading MedTech Contract Research Organization (CRO) offering global end-to-end development services to oversee the company's clinical trials investigating the Hemopurifier, Aethlon's immunotherapeutic device , for oncology indications.
- Zacks Small Cap Research
AEMD: Hemopurifier Hemopurifier To Be Studied in a Variety of Solid Tumors
By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Studying the Hemopurifier in a range of cancers Aethlon Medical’s (NASDAQ:AEMD) provided a business update. AEMD has been working to launch a blanket oncology trial to study the impact of the Hemopurifier on a variety of cancerous tumors. The company’s goal is to build its database in oncology to help with the development of the
